Intraosseous Infusion Devices Market Size & Share 2025 - 2034

Intraosseous Infusion Devices Market Size

The global intraosseous infusion devices market was valued at USD 949.1 million in 2024. The market is anticipated to grow from USD 997 million in 2025 to USD 1.66 billion in 2034, growing at a CAGR of 5.8% from 2025 to 2034. Intraosseous devices are specialized medical instruments that are utilized to transfer fluids, blood products, and drugs straight into the bone marrow, when intravenous (IV) access is not feasible or is delayed.

The increasing frequency of trauma related injuries, cardiac arrests, and medical emergencies throughout the world has resulted in a dramatic increase in the need for intraosseous infusion devices. As per the May 2025 study published by National Center for Biotechnology Information, the global burden of traumatic injuries is significant, with approximately 40 million individuals sustaining permanent injuries annually and nearly 6 million fatalities reported each year.
 

 Intraosseous infusion devices allow for rapid and reliable vascular access when veins are difficult to access, or fail to be accessible, in situations where time is of the essence, for example, patients suffering shock, or severe dehydration. Intraosseous access is essential intervention for emergency departments, ambulance services, and disaster medical response teams that use it to save lives in acute care settings.
 

The military and civilian medical services are also widely deploying intraosseous infusion devices for their portability, ease of operation, effective treatment in battlefield and field conditions. In some instances, intraosseous access offers the quickest treatment option to access rapid resuscitation, especially when venous capabilities are collapsed, or non-visible. The availability of intraosseous devices have propelled military, and regional emergency medical services (EMS) organizations procurement and training programs, creating additional market volumes, and a market outside the traditional hospital setting.
 

Further, new developments in technology associated with intraosseous infusion gear such as battery powered insertion devices, spring loaded devices, new designs in the tips of needles, has made procedures safer, quicker, and more uniform and are reducing the chances of complications and limiting user error, thereby improving the outcomes of patients faced with difficult emergency challenges. As technology continues to develop, the likelihood of clinicians using intraosseous devices will improve, particularly as new products are developed that allow for quicker use and greater reliability.
 

Intraosseous Infusion Devices Market Trends

• Global healthcare systems are increasingly integrating intraosseous infusion into trauma care protocols, including advanced trauma life support (ATLS) and pediatric advanced life support (PALS) guidelines.
   
• As intraosseous access becomes the preferred frontline option for managing hypovolemic shock, cardiac arrest, and failed intravenous access, hospitals and emergency medical service (EMS) teams are revising their protocols to align with this approach. This shift is driving consistent purchasing patterns, enhanced training programs, and broader adoption in clinical applications, particularly in high-acuity scenarios. Additionally, the market is witnessing a growing demand for compact, lightweight, and battery-operated intraosseous access systems, which are increasingly utilized by EMS, military personnel, and trained non-medical providers in field settings.
   
• Furthermore, to facilitate use of intraosseous infusion devices in field environments like ambulances, military zones, and disaster situations, next-generation intraosseous systems are being designed to be lighter, smaller, and more portable, so that EMS and tactical forces can carry intraosseous infusion systems in trauma bags or backpacks.
   
• The market is also witnessing a growing preference for sterile, single-use pre-packaged kits that include all necessary components for insertion. These kits enhance safety and minimize the risk of infection. Additionally, advancements in needle and catheter designs, such as improved tip geometry, depth control, and securement features, are effectively reducing complications like over-penetration and dislodgment.
   

Intraosseous Infusion Devices Market Analysis

In 2021, the global market was valued at USD 824.3 million. The following year, it saw an increase to USD 863 million, and by 2023, the market further climbed to USD 904.8 million. Based on product type, the global market is segmented into manual IO needles, battery-powered/automatic devices, and impact-driven devices. The battery-powered/automatic devices segment accounted for the highest market share and was valued at USD 457.8 million in 2024.
 

• Automatic intraosseous infusion devices, such as the Arrow EZ-IO, enable healthcare providers to achieve rapid vascular access, particularly in patients with trauma or shock-induced collapsed venous systems.
   
• In critical emergency scenarios, the speed and reliability of vascular access devices make them a preferred choice over traditional vascular access methods, establishing their importance in emergency medical services, emergency departments, and hypothermic care settings.
   
• Their consistent performance in high-stress, life-threatening situations has significantly contributed to their growing adoption, ensuring effective care delivery under challenging conditions.
   
• These devices are compact, durable, and require minimal operator training, making them ideal for use by emergency medical service teams, military medics, and disaster response personnel.
   
• The combination of ease of use, high first-attempt success rates, and minimal training requirements has driven the widespread adoption of automatic intraosseous infusion devices in emergency vehicles (ambulances and helicopters) and military field kits. This growth is further supported by government initiatives and investments aimed at strengthening emergency preparedness and enhancing combat casualty care capabilities.

Learn more about the key segments shaping this market

Download Free PDF

Based on the age group, the global intraosseous infusion devices market is categorized into pediatric patients and adult patients. The pediatric patients segment dominated the market with 68.2% market share in 2024.
 

• In pediatric emergency care, establishing IV access is often challenging due to the smaller and fragile veins of pediatric patients, particularly neonates and infants. For instance, as per the January 2023 study published by ScienceDirect, the first-attempt success rate for establishing peripheral intravenous catheters is approximately 77% in adults, whereas in pediatric patients, it drops to around 53%. Intraosseous infusion has emerged as a critical alternative for rapid fluid and drug administration when IV access proves difficult.
   
• The growing need for rapid and reliable vascular access in pediatric patients has driven the adoption of intraosseous access devices in pediatric intensive care units, emergency departments, and ambulance services globally.
   
• Global resuscitation protocols, such as Pediatric Advanced Life Support (PALS), recommend intraosseous access as the preferred route when IV access is not feasible, ensuring the timely delivery of life-saving fluids and medications to critically ill or injured children.
   
• The inclusion of intraosseous access devices in advanced life-support protocols has led to increased training and integration of intraosseous techniques in pediatric emergency medicine. This has also driven the demand for intraosseous devices specifically designed for pediatric applications, reflecting a growing organizational focus on improving emergency care outcomes for children.
   

Based on end use, the global intraosseous infusion devices market is classified into hospitals and clinics, ambulatory surgical centers, and other end users. In 2024, the hospitals and clinics segment held highest market share and is expected to showcase significant growth over the analysis period.
 

• The increasing incidence of severe trauma, cardiac arrest, hypovolemic shock, and sepsis is driving the demand for rapid vascular access solutions across hospitals and clinics globally.
   
• Intraosseous infusion has emerged as a critical solution in emergency care settings, including pre-hospital environments, trauma bays, and emergency departments. It is particularly effective in situations where intravenous access is challenging or delayed, such as in critically ill, obese, or pediatric patients, making it a preferred alternative for rapid vascular access.
   
• Prominent healthcare organizations, including the American Heart Association (AHA) and the European Resuscitation Council (ERC), have endorsed intraosseous access as a primary option when intravenous access is not viable. Its integration into guidelines for Advanced Cardiac Life Support (ACLS), Pediatric Advanced Life Support (PALS), and Advanced Trauma Life Support (ATLS) has further reinforced its adoption in emergency care protocols.
   
• Additionally, hospitals and emergency medical services are increasingly equipping themselves with intraosseous devices and training personnel in their use, contributing to the growing institutional demand for these systems.

The North America intraosseous infusion devices market dominated the global market in 2024, valuing at USD 424.2 million. The market dominance is attributed to the high volume of surgical procedures performed in U.S. and Canada, and widespread availability of advanced healthcare infrastructure.
 

The U.S. market was valued at USD 333.8 million and USD 349.1 million in 2021 and 2022, respectively. The market size reached USD 382.9 million in 2024, growing from USD 365.5 million in 2023.
 

• The U.S. records over 130 million emergency department visits annually, with a significant portion attributed to trauma, cardiac events, and severe dehydration, all of which necessitate rapid vascular access to stabilize patients.
   
• Intraosseous infusion devices have emerged as a reliable alternative when intravenous access is challenging, particularly for pediatric, elderly, and chronically ill patients. The high volume and diversity of emergency cases in the U.S. healthcare system underscore the critical role of intraosseous infusion devices in emergency response protocols.
   
• The U.S. boasts one of the most advanced emergency medical service (EMS) systems globally, featuring well-equipped ambulances, skilled paramedics, and extensive coverage, including remote areas. This infrastructure supports the widespread adoption of innovative technologies like intraosseous infusion devices.
   
• Portable, battery-powered intraosseous infusion devices, such as the Arrow EZ-IO, are now standard in pre-hospital settings, enabling faster fluid and drug administration during patient transport. The EMS sector's readiness to adopt advanced technologies has driven significant market penetration and sustained demand from state and municipal agencies.
   

Europe intraosseous infusion devices market accounted for USD 239.2 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe has well-established emergency care systems and trauma centers with standardized clinical practices. The presence of advanced emergency rooms and trained professionals in pre-hospital and rescue sectors supports the adoption of intraosseous infusion devices as a reliable alternative for rapid vascular access, particularly in complex cases involving pediatric, geriatric, and critically ill patients.
   
• European medical organizations, such as the European Resuscitation Council (ERC), have incorporated intraosseous access into their advanced life support guidelines, further validating its clinical importance.
   
• The harmonization of clinical guidelines across European countries facilitates standardized training and adoption, driving the increased utilization of intraosseous devices in both hospital and pre-hospital settings throughout the region.
   

Germany intraosseous infusion devices market is anticipated to witness considerable growth over the analysis period.
 

• Germany has a well-established emergency medical services (EMS) network characterized by short response times, advanced ambulance equipment, and specialized trauma centers. This robust infrastructure emphasizes the need for rapid vascular access in emergency scenarios, driving the demand for reliable intraosseous infusion devices, particularly in pre-hospital and hospital emergency care settings.
   
• Healthcare providers in Germany adhere to the European Resuscitation Council (ERC) advanced life support protocols, which recommend intraosseous access when intravenous access is challenging, delayed, or ineffective.
   
• The adoption of ERC protocols and national guidelines promoting intraosseous access as a standard practice encourages hospitals and emergency response teams to integrate intraosseous infusion devices into routine care. This trend is expected to drive growth in the intraosseous infusion device market in Germany.
   

The Asia Pacific intraosseous infusion devices market is anticipated to grow at the highest CAGR of 6.5% during the analysis timeframe.
 

• Several countries in the Asia-Pacific region are heavily investing in the development and enhancement of emergency medical services (EMS) and trauma care infrastructure.
   
• These advancements include developing new trauma care centers, equipping ambulances and hospitals with rapid intraosseous infusion devices to ensure swift vascular access during critical emergencies, particularly in urban areas. For instance, during the 11th Plan in India, a Trauma Care Scheme with an allocation of approximately USD 85 million was approved. The initiative aimed to establish a network of 140 trauma care facilities in government hospitals along the Golden Quadrilateral highway corridor, with 100% funding provided by the central government.
   
• In addition, urbanization, industrialization, and the rising number of vehicles in the Asia-Pacific region have led to an increase in trauma cases, including road traffic accidents and cardiovascular emergencies.
   
• This growing incidence of emergencies requiring immediate fluid resuscitation and drug delivery has driven the demand for vascular access solutions, such as intraosseous infusion devices, within the region's emergency medical care sector.
   

China intraosseous infusion devices market is predicted to grow significantly over the forecast period.
 

• The speed of urbanization and industrialization in China is having an impact on rates of road related accidents, workplace injuries, and urgent medical emergencies requiring immediacy of trauma care centers. According to September 2023 study published by National Institute for Biotechnology Information, in China, over 2 million individuals sustain injuries annually, with more than 600,000 fatalities reported due to trauma. This has driven the demand for intraosseous infusion devices, in hospitals and EMS settings in China.
   
• Furthermore, growing focus of government towards reducing the burden of trauma care is also driving the use of value-based care through using advanced trauma care devices such as intraosseous infusion devices in the country. As per the March 2025 study published by National Institute for Biotechnology Information, the direct medical expenses related to trauma treatment are estimated to reach approximately USD 9.05 billion annually in China.
   
• Further, China's continued healthcare reform and transformation features a focus on enhancing emergency medical systems and trauma systems for care. Entry of public sector funding and development aimed at integrated pre-hospital care and emergency departments has hastened the delivery of integrated intraosseous infusion devices throughout the nation.
   

Brazil is experiencing significant growth in the Latin America intraosseous infusion devices market due to the increasing demand for advanced intraosseous infusion devices in healthcare.
 

• Brazil faces a high incidence of trauma-related emergencies, including road traffic accidents and violence-related injuries, which necessitate efficient vascular access for fluid resuscitation and drug administration.
   
• According to data from DATASUS, provided by the Brazilian Ministry of Health, there were 30,149 deaths attributed to external causes (including accidents and violence) in 2023, with 30,010 deaths reported up to November 2024.
   
• Government and private sector investments in Brazil are driving advancements in emergency medical services infrastructure, including the expansion of ambulances and trauma centers. This growth is fueling the demand for intraosseous infusion devices, which enable rapid vascular access during patient transport and in emergency room settings.
   

Saudi Arabia intraosseous infusion devices market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The Saudi Arabian government is making substantial investments to modernize its healthcare system, with a strong emphasis on upgrading emergency medical services and trauma care infrastructure owing to increasing burden of trauma related injuries and fatalities.
   
• As per the Saudi Journal of Health System Research, the economic burden of road traffic accidents in Saudi Arabia exceeds USD 5.85 billion annually, highlighting the significant financial impact on the country's healthcare and emergency response systems.
   
• As part of the Vision 2030 initiative, efforts are being made by Government of Saudi Arabia to enhance pre-hospital and hospital emergency response capabilities, which is driving the adoption of intraosseous infusion devices, which provide rapid vascular access during critical emergencies.
   

Intraosseous Infusion Devices Market Share

The market is characterized by intense competition among established global players, regional manufacturers, and emerging firms. Leading companies, including Teleflex, Pyng Medical, PerSys Medical, Becton, Dickinson and Company, and Cardinal Health, collectively account for approximately 70% of the global market share. These key players employ strategies such as acquisitions, business expansion, and new product launches to maintain their competitive advantage. Additionally, numerous local and regional players contribute to heightened competition by offering cost-effective solutions. These players are actively pursuing strategies like mergers, acquisitions, and innovative product introductions to broaden their market presence and product portfolios.
 

Intraosseous Infusion Devices Market Companies

Few of the prominent players operating in the intraosseous infusion devices industry include:

• Aero Healthcare
• Becton, Dickinson and Company
• Biopsybell
• Bound Tree Medical
• Cardinal Health
• Cook Medical
• Henry Schein
• Implox
• PAVmed
• PerSys Medical
• Pyng Medical
• SAM Medical
• Sarnova
• Teleflex
• Vidacare
   
• Teleflex's EZ-IO System, a well-known battery-operated intraosseous infusion device, offers enhanced speed (insertion time in seconds), reliability, and FDA clearance for use in all ages; the device is widely recognized in EMS and military areas for its patented drill mechanism, disposable needles, and mechanisms that reduce complications, and its ability provoke real-time feedback (loss-of-resistance indicator).
   
• Pyng's FAST1 (adults) and FASTx (pediatrics) sternal intraosseous infusion system provide ultra-rapid vascular access (10 sec) through a new site, the sternum, an option not available by using tibial/humeral sites. The design is a single-step, needle-free, which minimizes insertion pain, and has the least potential for complications to occur. The FAST system is a preferred method for providing intraosseous access during mass-casualty events, and military operations or exercises, which is largely attributable to its small, lightweight, and compact (no moving parts) design.
   
• PerSys offers an NIO (New Intraosseous) device as competition, which has the ability to be used with single hand. The device features a silent drill and utilizes sharper needles to allow near painless insertion. The auto retracting safety mechanism reduces needlestick, and the universal battery (AA) allows for field readiness.
   

Intraosseous Infusion Devices Industry News

• In October 2024, Becton, Dickinson and Company, a leading global medical technology company, announced the launch of its new BD Intraosseous Vascular Access System, enabling access for rapid delivery of fluids or medication in critical emergency situations. This launch is expected to strengthen Becton, Dickinson and Company’s emergency care portfolio, enhance its position in the intraosseous access market, and support its commitment to improving clinical outcomes in high-acuity settings.
   
• In May 2024, Teleflex, a key player in medical technologies and pioneer in intraosseous vascular access, today announced the launch of the Arrow EZ-IO Intraosseous Access Procedure Tray. The launch is anticipated to reinforce Teleflex’s leadership in intraosseous access solutions, improve procedural efficiency in emergency care settings, and support the company’s broader strategy of delivering integrated, clinician-focused innovations.
   
• In March 2020, SAM Medical, an industry leader committed to developing and manufacturing innovative trauma care medical devices, announced the launch of the SAM IO Intraosseous Access System for prehospital and hospital healthcare providers in the civilian and military sectors. The launch is expected to expand SAM Medical’s footprint in the intraosseous access market, strengthen its offerings in both civilian and tactical emergency care, and align with its mission to deliver rapid, reliable solutions for critical care scenarios.
   

The intraosseous infusion devices market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Manual IO needles
• Battery-powered/automatic devices
• Impact-driven devices

Market, By Age Group

• Pediatric patients
• Adult patients

Market, By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE